WO2017191987A1 - Nasolacrimal duct tube and mechanism for inserting nasolacrimal duct - Google Patents

Nasolacrimal duct tube and mechanism for inserting nasolacrimal duct Download PDF

Info

Publication number
WO2017191987A1
WO2017191987A1 PCT/KR2017/004663 KR2017004663W WO2017191987A1 WO 2017191987 A1 WO2017191987 A1 WO 2017191987A1 KR 2017004663 W KR2017004663 W KR 2017004663W WO 2017191987 A1 WO2017191987 A1 WO 2017191987A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
tube
nasal
nasolacrimal
delivery system
Prior art date
Application number
PCT/KR2017/004663
Other languages
French (fr)
Korean (ko)
Inventor
임한웅
Original Assignee
한양대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한양대학교 산학협력단 filed Critical 한양대학교 산학협력단
Publication of WO2017191987A1 publication Critical patent/WO2017191987A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00772—Apparatus for restoration of tear ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention relates to a nasolacrimal tube and a device for nasolacrimal duct insertion.
  • intraocular drug delivery is performed by intraocular injection, eye drop, or the like, but there are problems such as lack of patient compliance, incongruity of dosing schedule, and cost of dosing. Therefore, in order to solve this problem, eye drug delivery using a nasal drainage system is being studied.
  • Representative ophthalmic drug delivery method using a nasal discharge system is a punctual plug. This is a method of inserting a punctal stopper containing a drug into the punctate. This will be described with reference to FIG. 1.
  • FIG. 1 is a view showing a punctual plug for ophthalmic drug delivery according to the prior art.
  • the punctal stopper 10 includes a medicine in the internal space 20.
  • the punctal stopper 10 is inserted into the punctate of the patient, and when the tear and the drug meet, the drug is melted and discharged.
  • the ophthalmic drug delivery method using the punctal stopper may be lost, the drug is dissolved and discharged, the depth of the drug is lowered, the amount of the drug discharge may decrease over time. Accordingly, there is a risk that the patient's vision may be impaired or the patient may be blind because the drug is not properly delivered to the patient.
  • the nasolacrimal duct tube inserted along the nasolacrimal duct according to an embodiment of the present invention and having a flexibility includes a medicament accommodating portion accommodating a medicament, a medicament discharging portion discharging the medicament to the outside of the nasolacrimal duct tube, and a medicament accommodating portion. And a medicament delivery system for delivering the medicament to the medicament outlet through the nasal duct tube.
  • Nasal duct insertion apparatus a nasal duct tube inserted along the nasal duct and having a flexible, drug receiving portion for receiving the drug, the drug is formed so that the drug can be discharged to the outside of the nasal duct tube And a drug delivery system for delivering the drug contained in the discharge part and the drug receiving part to the drug discharge part through the nasal duct tube.
  • the drug can be delivered to the patient stably and continuously.
  • systemic and sustained administration of the drug is possible without the drug passing through the liver.
  • FIG. 1 is a view showing a punctual plug for ophthalmic drug delivery according to the prior art.
  • FIG. 2 is a view showing a nasolacrimal duct tube according to an embodiment of the present invention.
  • FIG 3 is a cross-sectional view of the nasolacrimal tube and the drug delivery route according to an embodiment of the present invention.
  • Figure 4 is a view showing a state in which the nasolacrimal duct tube is inserted into the human body according to an embodiment of the present invention.
  • Figure 5 is a view showing the position of the drug discharge portion in the nasolacrimal duct tube according to an embodiment of the present invention.
  • Figure 6 is a view showing the position of the drug receiving portion in the nasolacrimal duct tube according to an embodiment of the present invention.
  • FIG. 7 is a view showing a drug delivery system including an elastic member according to an embodiment of the present invention.
  • FIG. 8 is a view showing a drug delivery system including an expandable substance receiving unit according to an embodiment of the present invention.
  • FIG. 9 is a view showing a drug delivery system including a reactant receiving portion and a reaction portion according to an embodiment of the present invention.
  • FIG. 10 is a view showing the position of the drug delivery system in the nasolacrimal tube according to an embodiment of the present invention.
  • FIG. 2 is a view showing a nasolacrimal duct tube according to an embodiment of the present invention.
  • the nasolacrimal duct 200 is inserted along the nasolacrimal duct, has flexibility, and includes a drug discharge unit 210, a drug receiving unit 220, and a drug delivery system ( 230).
  • the drug discharge part 210 is formed to allow the drug to be discharged to the outside of the nasolacrimal duct 200.
  • the drug in the nasolacrimal duct 200 may be delivered to the eye through the drug outlet 210.
  • the drug discharge unit 210 is formed to be openable and control the drug discharge. More specifically, the drug discharge unit 210 may be formed in the form of a valve to allow or block the discharge of the drug. Through this configuration it is possible to control the amount of drug discharged as desired.
  • the drug discharge unit 210 may include at least one or more openings (211).
  • the number, shape, and size of the openings 211 may be variously configured. This will be described with reference to FIG. 3.
  • FIG 3 is a cross-sectional view of the nasolacrimal tube and the drug delivery route according to an embodiment of the present invention.
  • the medicament may flow to the eye through the opening 211 along the medicament delivery path 240.
  • the opening 211 may penetrate from the outside to the inside of the nasolacrimal tube 200 in a direction perpendicular to the surface, or may be obliquely penetrated.
  • the drug discharge portion 210 is a position corresponding to at least one or more points of punctal and nasal passages when the nasolacrimal tube 200 is inserted
  • Figure 4 is a view showing a state in which the nasolacrimal duct tube is inserted into the human body according to an embodiment of the present invention
  • Figure 5 is a view showing the position of the drug discharge portion in the nasolacrimal duct tube according to an embodiment of the present invention.
  • the drug outlets 212 and 213 correspond to at least one or more points of the punctal 41a and 41b and the nasal passage 42.
  • the drug discharged from the drug discharge unit 210 may be stably delivered to the eye through the punctuation.
  • the drug discharge unit 213 is formed at the position 213 corresponding to the nasal passage, the drug discharged from the drug discharge unit 210 may be absorbed by the human body through the nasal mucosa 43.
  • the nasal passage 42 has two strands of nasolacrimal duct 200.
  • the drug outlet 213 may be formed in only one strand of nasolacrimal duct 200, or may be formed in both strands.
  • FIGS. 4 and 5 are for explaining the position of the drug discharge unit 210 in the nasal duct tube 200, the configuration other than the drug discharge unit 210 is omitted.
  • the drug receiving unit 220 and the drug delivery system 230 may be configured in various forms.
  • the drug receiving unit 220 receives a drug.
  • the drug receiving unit 220 is a drug for delivering to the eye, artificial tears, antibiotics, immunosuppressive agents, intraocular pressure lowering agents, analgesic anti-inflammatory drugs, steroids, antihistamines, dry eye treatments, etc. can do.
  • the drug receiving unit 220 is a drug to be absorbed by the human body through the nasal mucosa 43, it may contain a blood pressure lowering agent, vasodilator, diabetes treatment.
  • the drug receiving unit 220 may be located at one end or both ends of the nasolacrimal tube 200.
  • the drug receiving unit 220 is located at both ends of the nasolacrimal duct 200, it is possible to receive a larger amount of drug than to be located only once.
  • the position of the drug receiving unit 220 is not limited thereto, and the drug receiving unit 220 may be located at the center of the nasolacrimal tube 200. In particular, the drug receiving unit 220 may be located between the plurality of drug discharge unit 210, when a plurality of drug discharge unit 210 is formed. It demonstrates with reference to FIG.
  • Figure 6 is a view showing the position of the drug receiving portion in the nasolacrimal duct tube according to an embodiment of the present invention.
  • the drug receiving unit 220 is positioned between the plurality of drug discharge units 210.
  • 6 illustrates a structure in which the drug delivery system 230 is located at the rear of the drug discharge unit 210 and pushes the drug contained in the drug receiving unit 220 to deliver the drug to the drug discharge unit 210.
  • the drug receiving portion 220 located between the discharge portion 210 is shown in two. However, in the structure in which the drug delivery system 230 is located in front of the drug discharge unit 210 to draw the drug contained in the drug receiving unit 220 to deliver to the drug discharge unit 210 a plurality of drug discharge unit 210 There may be one drug receiving unit 220 located therebetween, and at this time, the drug delivery system 230 may be two.
  • the location structure of the drug receiving unit 220 and the drug delivery system 230 will be described in detail below.
  • the dose of the drug receiving unit 220 may vary depending on the thickness of the nasolacrimal tube 200. That is, the larger the nasal tube tube 200, the larger the dose of the drug receiving unit 220, the thinner the nasal tube tube 200, the smaller the dose of the drug receiving unit 220 may be. Therefore, the thickness of the nasolacrimal tube 200 may be determined according to the dosage. For example, in the case of dry eye patients, since the administration of artificial tears is required in a short cycle and a large dose of the drug receiving unit 220 is required, the thick nasolacrimal tube 200 may be selected. On the contrary, when the dosage is small, the thin nasolacrimal tube 200 may be selected.
  • the drug receiving portion 200 may be formed detachably to the nasolacrimal tube 200.
  • the drug receiving unit 200 By configuring the drug receiving unit 200 to be detachable, it is possible to more conveniently replenish the medicine while replacing the nasolacrimal tube 200 to the patient, or replace with another medicine.
  • the drug receiving unit 200 may be detachable alone, or may be detached like the drug delivery system 230.
  • the drug delivery system 230 delivers the drug contained in the drug receiving unit 220 to the drug discharge unit 210 through the nasolacrimal tube 200.
  • the drug delivery system 230 may include a piston 240 for moving the drug.
  • the piston 240 may move the drug by pushing or dragging the drug.
  • the drug delivery system 230 is formed at the rear of the drug receiving unit 220, it can push the drug contained in the drug receiving unit 230 to deliver to the drug discharge unit 210.
  • the drug delivery system 230 is formed at the rear of the drug receiver 220 based on the drug discharge unit 210. In this structure, the drug delivery system 230 pushes the drug contained in the drug receiving unit 220 and delivers the drug to the drug discharge unit 210.
  • the drug delivery system 230 may include at least one or more of the elastic member 710 and the expansion material receiving portion 810 for receiving the expansion material.
  • the drug delivery system 230 may include at least one or more reactant accommodating portions 910 and 920 respectively accommodating at least two or more reactants and a reacting portion 930 where the at least two or more reactants meet and react. have. This will be described with reference to FIGS. 7 to 9.
  • FIG. 7 is a view showing a drug delivery system including an elastic member according to an embodiment of the present invention.
  • one side of the elastic member 710 is connected to the piston 240 that separates the drug receiving unit 220 and the drug delivery system 230, and the other side is fixed.
  • the elastic member 710 pushes the piston 240 to push out the medicine contained in the medicine container 220.
  • various members such as a spring and a shape memory alloy having a restoring force, may be used.
  • the coil spring is shown as an elastic member 710.
  • the elastic member 710 condenses energy and, when triggered under a specific condition, pushes the piston 240 by the restoring force.
  • the specific condition may be a temperature, a user's operation, or the like.
  • FIG. 8 is a view showing a drug delivery system including an expandable substance receiving portion according to an embodiment of the present invention.
  • one side of the expanded material receiver 810 is connected to a piston 240 that separates the drug receiver 220 and the drug delivery system 230, and the other side is fixed.
  • the expansion material contained in the expansion material receiver 810 expands and pushes the piston 240 to push out the medicine contained in the medicine receiver 220.
  • the expandable material may be a gas or a liquid which expands at a certain temperature, preferably at or near room temperature. This expansion material, when triggered under certain conditions, initiates expansion and pushes the piston 240.
  • the specific condition may be temperature, air pressure, and the like.
  • the inflation substance receiver 810 and the drug delivery system 230 are shown identically. However, the present invention is not limited thereto, and the drug delivery system 230 and the expandable material receiver 810 may be separated from each other by a method such that the expanded material receiver 810 is located in the drug delivery system 230.
  • FIG. 9 is a view showing a drug delivery system including a reactant receiving portion and a reaction portion according to an embodiment of the present invention.
  • one side of the reaction unit 930 is connected to the piston 240 that separates the drug receiving unit 220 and the drug delivery system 230, and the other side is fixed.
  • the first reactant accommodating part 910 and the second reactant accommodating part 920 are separated by a blocking film 940.
  • the blocking layer 940 is removed under specific conditions, the first reactant and the second reactant contained in the first reactant accommodating part 910 and the second reactant accommodating part 920 react in the reaction part 930.
  • the piston 240 pushes the drug contained in the drug receiving portion 220.
  • Reactive materials may be a material that meets and reacts with each other and expands.
  • the blocking film 940 according to an embodiment of the present invention may be removed at an external force or a specific temperature.
  • the first reactant accommodating part 910 and the second reactant accommodating part 920 are divided into the blocking film 940 in FIG. 9, they may be separated by other various methods.
  • the reaction unit 930 and the drug delivery system 230 are shown in the same manner, and the first reactant accommodating part 910 and the second reactant accommodating part 920 are formed in the reaction part 930. Included.
  • the reaction unit 930 is located in the drug delivery system 230, and the reaction unit 930 is a separate space from the first reactant accommodating part 910 and the second reactant accommodating part 920.
  • the drug delivery system 230 and the reaction unit 930, the first reactant accommodating part 910, and the second reactant accommodating part 920 may be separated from each other.
  • the drug delivery system 230 is formed in front of the drug receiving unit 220, may be delivered to the drug discharge unit 210 by pulling the drug contained in the drug receiving unit 220. . It demonstrates with reference to FIG.
  • FIG. 10 is a view showing the position of the drug delivery system in the nasolacrimal tube according to an embodiment of the present invention.
  • the drug delivery system 230 is formed at the front of the drug receiving unit 220 based on the drug discharge unit 210.
  • the drug delivery system 230 pulls the drug contained in the drug receiving unit 220 and delivers the drug to the drug discharge unit 210.
  • the drug delivery system 230 may comprise a pump (not shown).
  • the pump may be an airless pump.
  • the pump may pump the medicine contained in the medicine container and deliver the medicine to the medicine discharge part.
  • the drug delivery system 230 may be detachably formed in the nasolacrimal tube 200.
  • the drug delivery system 230 may be detachable, when the energy (elastic energy, reaction energy, etc.) of the drug delivery system 230 is exhausted, the drug delivery system 230 may be replaced more conveniently.
  • the drug delivery system 230 may be detachably detached, or may be detachably attached to the drug receiving unit 200.
  • the nasolacrimal duct tube 200 may be formed to a thickness that does not block the punctate so that tears can be smoothly discharged even when the nasolacrimal duct 200 is inserted. More specifically, the nasolacrimal duct 200 may be formed to a thickness such that the circumference thereof is smaller than the average puncturing circumference of the person. At this time, in order to smooth the discharge of tears nasal tube tube 200 may be formed thinner than other positions in the position corresponding to the punctate.
  • the material of the flexible tube according to the embodiment of the present invention may be silicon.
  • a material having a hardness rather than a silicon tube to facilitate insertion into the fistula.
  • it may be composed of a material selected from the group of polyolefins, polyamides or polyurethanes alone or mixtures thereof.
  • the drug can be delivered to the patient stably and continuously.
  • systemic and sustained administration of the drug is possible without the drug passing through the liver.
  • the nasal tube tube 200 is inserted along the nasolacrimal tube and flexible, the drug receiving unit 220 for receiving a drug, the drug is discharged to the outside of the nasal tube tube It includes a drug delivery system 230 to deliver the drug contained in the drug discharge unit 210 and the drug receiving unit 220 to the drug discharge unit 210 through the nasal duct tube 200.
  • a drug delivery system 230 to deliver the drug contained in the drug discharge unit 210 and the drug receiving unit 220 to the drug discharge unit 210 through the nasal duct tube 200.
  • Each configuration is the same as the configuration of the nasolacrimal tube described above, so that duplicate description will be omitted.
  • the nasolacrimal catheter insertion apparatus may further include a pair of probes or guides inserted at both ends of the nasolacrimal tube and flexible.
  • a pair of probes or guides inserted at both ends of the nasolacrimal tube and flexible.
  • Such a form of a tube or probe or guide inserted along the nasolacrimal duct and having flexibility may have various forms within the scope obvious to those skilled in the art.
  • nasolacrimal duct insertion instrument may be inserted in the following manner.
  • the probes are respectively inserted through the upper and lower punctures 41a and 41b, and withdrawn to the outside, and the nasolacrimal tube 200 is inserted into the nasal passages 42 from the puncturing holes 41a and 41b by the guiding action of the probes. can do.
  • the position of the nasal duct tube 200 may be adjusted such that the drug discharge part 210 is positioned in the punctal tract 41a or 41b or the nasal passage 42.
  • the nasolacrimal tube 200 may include a length adjusting unit, and the length and position of the nasolacrimal tube 200 may be adjusted such that the drug discharge unit 210 is positioned at a desired position using the length adjusting unit.
  • the probe is detached from the tube 200 and the nasal tube tube 200 is knotted to form a nodule, thereby fixing the nasolacrimal tube 200 so that the nasolacrimal tube 200 is inserted into the body. It is possible to maintain the communication status of the male fistula.
  • the mounting method of the nasolacrimal insertion device may also be variously made within a range obvious to those skilled in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

The present invention relates to a nasolacrimal duct tube and a mechanism for inserting a nasolacrimal duct. A nasolacrimal duct tube which is inserted along a nasolacrimal duct and has flexibility, according to one embodiment of the present invention, comprises: a drug accommodation unit for accommodating a drug; a drug discharge unit for discharging the drug out of the nasolacrimal duct tube; and a drug delivery system for delivering the drug accommodated in the drug accommodation unit to the drug discharge unit via the nasolacrimal duct tube.

Description

비루관 튜브 및 비루관 삽입용 기구Nasal tube and instrument for inserting nasal tube
본 발명은 비루관 튜브 및 비루관 삽입용 기구에 관한 것이다.The present invention relates to a nasolacrimal tube and a device for nasolacrimal duct insertion.
인간의 눈물은 윗눈꺼풀 뒤편에 있는 눈물샘에서 만들어져서 누점이라고 하는 구멍으로 흘러 누낭에 모인 뒤 비루관을 지나 비도(코)로 배출된다. 이러한 시스템을 비루배출계(nasolacrimal drainage system)라 한다. 최근 이러한 비루배출계를 이용한 약물 전달(ocular drug delivery)이 연구되고 있다.Human tears are made from the lacrimal glands at the back of the upper eyelid, flow into a hole called the punctate, collect in the lacrimal sac, and pass through the nasolacrimal duct to the nasal passages. Such a system is called a nasolacrimal drainage system. Recently, drug delivery (ocular drug delivery) using such a nasal discharge system has been studied.
종래 기술에 따르면, 안내 주사, 점안액 점적 등의 방법으로 안 약물 전달을 실시하고 있으나, 환자 순응도의 결여, 투약 계획의 부조화, 투약 비용 등의 문제가 있다. 따라서, 이러한 문제를 해결하기 위하여 비루배출계를 이용한 안 약물 전달이 연구되고 있는 것이다.According to the prior art, intraocular drug delivery is performed by intraocular injection, eye drop, or the like, but there are problems such as lack of patient compliance, incongruity of dosing schedule, and cost of dosing. Therefore, in order to solve this problem, eye drug delivery using a nasal drainage system is being studied.
대표적인 비루배출계를 이용한 안 약물 전달 방법으로 누점 마개(punctual plug)를 이용하는 방법이 있다. 이는 약제를 포함하는 누점 마개를 누점에 삽입하는 방법이다. 도 1을 참조하여 설명하도록 한다.Representative ophthalmic drug delivery method using a nasal discharge system is a punctual plug. This is a method of inserting a punctal stopper containing a drug into the punctate. This will be described with reference to FIG. 1.
도 1은 종래 기술에 따른 안 약물 전달을 위한 누점 마개(punctual plug)를 도시한 도면이다.1 is a view showing a punctual plug for ophthalmic drug delivery according to the prior art.
도 1을 참조하면, 누점 마개(10)는 내부 공간(20)에 약제를 포함하고 있다. 이러한 누점 마개(10)는 환자의 누점에 삽입되어, 눈물과 약제가 만나면, 약제가 녹아 배출되도록 구성된다.Referring to FIG. 1, the punctal stopper 10 includes a medicine in the internal space 20. The punctal stopper 10 is inserted into the punctate of the patient, and when the tear and the drug meet, the drug is melted and discharged.
하지만, 누점 마개를 이용한 안 약물 전달 방법은, 누점 마개가 유실될 수 있고, 약제가 녹아 배출됨에 따라 약제의 깊이가 낮아져 시간이 지남에 따라 약제의 배출양이 줄어들 수 있다는 문제가 있다. 이에 따라 환자에게 적절하게 약물이 전달되지 못해 환자의 시력이 감퇴되거나, 환자가 실명될 위험이 있다.However, the ophthalmic drug delivery method using the punctal stopper, the punctal stopper may be lost, the drug is dissolved and discharged, the depth of the drug is lowered, the amount of the drug discharge may decrease over time. Accordingly, there is a risk that the patient's vision may be impaired or the patient may be blind because the drug is not properly delivered to the patient.
본 발명은 환자에게 안정적이고 지속적으로 약제를 전달할 수 있는 비루관 튜브 및 이러한 튜브를 포함하는 비루관 삽입용 기구를 제공하는 것을 그 목적으로 한다. 또한, 본 발명은 비도를 통해 약제의 전신적이고 지속적인 투약이 가능한 비루관 튜브 및 이러한 튜브를 포함하는 비루관 삽입용 기구를 제공하는 것을 그 목적으로 한다.It is an object of the present invention to provide a nasolacrimal duct tube capable of delivering a medicament stably and continuously to a patient and a device for insertion of nasolacrimal ducts including such a tube. It is also an object of the present invention to provide a nasolacrimal duct tube capable of systemic and continuous administration of a medicament via the nasal passage and a nasolacrimal tube insertion instrument including such a tube.
본 발명의 일 실시예에 따른 비루관을 따라 삽입되고 가요성을 갖는 비루관 튜브는, 약제를 수용하는 약제 수용부, 상기 약제가 상기 비루관 튜브의 외부로 배출되는 약제 배출부 및 상기 약제 수용부에 수용된 상기 약제를 상기 비루관 튜브를 통해 상기 약제 배출부로 전달하는 약제 전달 시스템을 포함한다.The nasolacrimal duct tube inserted along the nasolacrimal duct according to an embodiment of the present invention and having a flexibility includes a medicament accommodating portion accommodating a medicament, a medicament discharging portion discharging the medicament to the outside of the nasolacrimal duct tube, and a medicament accommodating portion. And a medicament delivery system for delivering the medicament to the medicament outlet through the nasal duct tube.
본 발명의 일 실시예에 따른 비루관 삽입용 기구는, 비루관을 따라 삽입되고 가요성을 갖는 비루관 튜브, 약제를 수용하는 약제 수용부, 상기 약제가 상기 비루관 튜브의 외부로 배출될 수 있도록 형성되는 약제 배출부 및 상기 약제 수용부에 수용된 상기 약제를 상기 비루관 튜브를 통해 상기 약제 배출부로 전달하는 약제 전달 시스템을 포함한다.Nasal duct insertion apparatus according to an embodiment of the present invention, a nasal duct tube inserted along the nasal duct and having a flexible, drug receiving portion for receiving the drug, the drug is formed so that the drug can be discharged to the outside of the nasal duct tube And a drug delivery system for delivering the drug contained in the discharge part and the drug receiving part to the drug discharge part through the nasal duct tube.
본 발명에 따르면, 환자에게 안정적이고 지속적으로 약물을 전달할 수 있다. 또한, 약제가 간을 통과하지 않으면서도 약제의 전신적이고 지속적인 투약이 가능하다.According to the present invention, the drug can be delivered to the patient stably and continuously. In addition, systemic and sustained administration of the drug is possible without the drug passing through the liver.
도 1은 종래 기술에 따른 안 약물 전달을 위한 누점 마개(punctual plug)를 도시한 도면이다.1 is a view showing a punctual plug for ophthalmic drug delivery according to the prior art.
도 2는 본 발명의 일 실시예에 따른 비루관 튜브를 도시한 도면이다.2 is a view showing a nasolacrimal duct tube according to an embodiment of the present invention.
도 3은 본 발명의 일 실시예에 따른 비루관 튜브의 단면과 약제 전달 경로를 도시한 도면이다.3 is a cross-sectional view of the nasolacrimal tube and the drug delivery route according to an embodiment of the present invention.
도 4는 본 발명의 일 실시예에 따른 비루관 튜브가 인체에 삽입된 상태를 도시한 도면이다.Figure 4 is a view showing a state in which the nasolacrimal duct tube is inserted into the human body according to an embodiment of the present invention.
도 5는 본 발명의 일 실시에에 따른 비루관 튜브에서 약제 배출부의 위치를 나타내는 도면이다.Figure 5 is a view showing the position of the drug discharge portion in the nasolacrimal duct tube according to an embodiment of the present invention.
도 6은 본 발명의 일 실시예에 따른 비루관 튜브에서 약제 수용부의 위치를 나타내는 도면이다.Figure 6 is a view showing the position of the drug receiving portion in the nasolacrimal duct tube according to an embodiment of the present invention.
도 7은 본 발명의 일 실시예에 따른 탄성 부재를 포함하는 약제 전달 시스템을 나타내는 도면이다.7 is a view showing a drug delivery system including an elastic member according to an embodiment of the present invention.
도 8은 본 발명의 일 실시예에 따른 팽창 물질 수용부를 포함하는 약제 전달시스템을 나타내는 도면이다.8 is a view showing a drug delivery system including an expandable substance receiving unit according to an embodiment of the present invention.
도 9은 본 발명의 일 실시예에 따른 반응 물질 수용부 및 반응부를 포함하는 약제 전달 시스템을 나타내는 도면이다.9 is a view showing a drug delivery system including a reactant receiving portion and a reaction portion according to an embodiment of the present invention.
도 10은 본 발명의 일 실시예에 따른 비루관 튜브에서 약제 전달 시스템의 위치를 나타내는 도면이다.10 is a view showing the position of the drug delivery system in the nasolacrimal tube according to an embodiment of the present invention.
이하, 첨부된 도면을 참조하여 본 발명의 바람직한 실시 예들을 상세히 설명한다. 이 때, 첨부된 도면에서 동일한 구성 요소는 가능한 동일한 부호로 나타내고 있음에 유의해야 한다. 또한 본 발명의 요지를 흐리게 할 수 있는 공지 기능 및 구성에 대한 상세한 설명은 생략할 것이다.Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings. At this time, it should be noted that the same components in the accompanying drawings are represented by the same reference numerals as possible. In addition, detailed descriptions of well-known functions and configurations that may blur the gist of the present invention will be omitted.
도 2는 본 발명의 일 실시예에 따른 비루관 튜브를 도시한 도면이다.2 is a view showing a nasolacrimal duct tube according to an embodiment of the present invention.
도 2를 참조하면, 본 발명의 일 실시예에 따른 비루관 튜브(200)는, 비루관을 따라 삽입되고, 가요성을 가지며, 약제 배출부(210), 약제 수용부(220) 및 약제 전달 시스템(230)을 포함한다.2, the nasolacrimal duct 200 according to an embodiment of the present invention is inserted along the nasolacrimal duct, has flexibility, and includes a drug discharge unit 210, a drug receiving unit 220, and a drug delivery system ( 230).
약제 배출부(210)는 약제가 비루관 튜브(200)의 외부로 배출될 수 있도록 형성된다. 이러한 약제 배출부(210)를 통해 비루관 튜브(200) 내의 약제가 눈으로 전달될 수 있다. 본 발명의 일 실시예에 따르면, 약제 배출부(210)는 개폐 가능하도록 형성되어 약제 배출을 조절할 수 있다. 보다 구체적으로, 약제 배출부(210)는 밸브 형태로 형성되어 약제 배출을 허용하거나 차단할 수 있다. 이러한 구성을 통해 원하는 대로 배출되는 약제의 양을 조절할 수 있다.The drug discharge part 210 is formed to allow the drug to be discharged to the outside of the nasolacrimal duct 200. The drug in the nasolacrimal duct 200 may be delivered to the eye through the drug outlet 210. According to one embodiment of the present invention, the drug discharge unit 210 is formed to be openable and control the drug discharge. More specifically, the drug discharge unit 210 may be formed in the form of a valve to allow or block the discharge of the drug. Through this configuration it is possible to control the amount of drug discharged as desired.
또한, 본 발명의 일 실시예에 따르면, 약제 배출부(210)는 적어도 하나 이상의 개구부(211)를 포함할 수 있다. 이러한 개구부(211)의 개수나 형태, 크기는 다양하게 구성될 수 있다. 도 3을 참조하여 설명하도록 한다.In addition, according to one embodiment of the present invention, the drug discharge unit 210 may include at least one or more openings (211). The number, shape, and size of the openings 211 may be variously configured. This will be described with reference to FIG. 3.
도 3은 본 발명의 일 실시예에 따른 비루관 튜브의 단면과 약제 전달 경로를 도시한 도면이다.3 is a cross-sectional view of the nasolacrimal tube and the drug delivery route according to an embodiment of the present invention.
도 3을 참조하면, 약제는 약제 전달 경로(240)를 따라 개구부(211)를 통과하여 눈으로 흐를 수 있다. 본 발명의 일 실시예에 따르면, 개구부(211)는 표면에 수직방향으로 비루관 튜브(200)의 외부에서 내부까지 관통될 수도 있고, 비스듬히 경사지게 관통될 수도 있다.Referring to FIG. 3, the medicament may flow to the eye through the opening 211 along the medicament delivery path 240. According to one embodiment of the present invention, the opening 211 may penetrate from the outside to the inside of the nasolacrimal tube 200 in a direction perpendicular to the surface, or may be obliquely penetrated.
다시 도 2의 설명으로 돌아가면, 약제 배출부(210)는 적어도 하나 이상 형성될 수 있다. 특히, 본 발명에 일 실시예에 따른 약제 배출부(210)는 비루관 튜브(200) 삽입 시 누점 및 비도 중 적어도 하나 이상의 지점에 대응되는 위치2 again, at least one drug outlet 210 may be formed. In particular, the drug discharge portion 210 according to an embodiment of the present invention is a position corresponding to at least one or more points of punctal and nasal passages when the nasolacrimal tube 200 is inserted
에 형성될 수 있다. 도 4를 참조하여 설명하도록 한다.Can be formed on. This will be described with reference to FIG. 4.
도 4는 본 발명의 일 실시예에 따른 비루관 튜브가 인체에 삽입된 상태를 도시한 도면이고, 도 5는 본 발명의 일 실시에에 따른 비루관 튜브에서 약제 배출부의 위치를 나타내는 도면이다.Figure 4 is a view showing a state in which the nasolacrimal duct tube is inserted into the human body according to an embodiment of the present invention, Figure 5 is a view showing the position of the drug discharge portion in the nasolacrimal duct tube according to an embodiment of the present invention.
도 4 및 도 5를 참조하면, 약제 배출부(212, 213)는 비루관 튜브(200)가 인체에 삽입된 경우, 누점(41a, 41b) 및 비도(42)에 중 적어도 하나 이상의 지점에 대응되는 위치에 형성될 수 있다. 즉, 약제 배출부(212)는 누점(41a,41b)에 대응되는 위치에 형성될 수도 있고, 약제 배출부(213)가 비도(42)에 대응되는 위치에 형성될 수도 있으며, 약제 배출부(212, 213)가 누점(41a, 41b) 및 비도(42)에 대응되는 위치에 모두 형성될 수 있다.4 and 5, when the nasal duct tube 200 is inserted into the human body, the drug outlets 212 and 213 correspond to at least one or more points of the punctal 41a and 41b and the nasal passage 42. Can be formed in position. That is, the drug discharge unit 212 may be formed at a position corresponding to the punctum 41a, 41b, the drug discharge unit 213 may be formed at a position corresponding to the nasal passage 42, and the drug discharge unit ( 212 and 213 may be formed at both positions corresponding to the puncta 41a and 41b and the nasal passage 42.
약제 배출부(212)가 누점에 대응되는 위치에 형성되는 경우, 약제 배출부(210)에서 배출되는 약제가 누점을 통과해 눈으로 안정적으로 전달될 수 있다. 또한, 약제 배출부(213)가 비도에 대응되는 위치(213)에 형성되는 경우, 약제 배출부(210)에서 배출되는 약제가 비도의 점막(43)을 통해 인체에 흡수될 수 있다. 따라서, 약제가 간을 통과하지 않으면서도 약제의 전신적 투약이 가능하다. 이때, 도 4에서 도시한 바와 같이 비도(42)에는 두 가닥의 비루관 튜브(200)가 위치한다. 약제 배출부(213)는 한 가닥의 비루관 튜브(200)에만 형성될 수도 있고, 두 가닥 모두에 형성될 수도 있다.When the drug discharge unit 212 is formed at a position corresponding to the punctuation, the drug discharged from the drug discharge unit 210 may be stably delivered to the eye through the punctuation. In addition, when the drug discharge unit 213 is formed at the position 213 corresponding to the nasal passage, the drug discharged from the drug discharge unit 210 may be absorbed by the human body through the nasal mucosa 43. Thus, systemic administration of the drug is possible without the drug passing through the liver. In this case, as shown in Figure 4, the nasal passage 42 has two strands of nasolacrimal duct 200. The drug outlet 213 may be formed in only one strand of nasolacrimal duct 200, or may be formed in both strands.
도 4 및 도 5는 비루관 튜브(200)에서 약제 배출부(210)의 위치를 설명하기 위한 것으로, 약제 배출부(210) 이외의 구성은 생략하였다. 도 4 및 도 5에서 약제 수용부(220) 및 약제 전달 시스템(230)은 다양한 형태로 구성될 수 있다.4 and 5 are for explaining the position of the drug discharge unit 210 in the nasal duct tube 200, the configuration other than the drug discharge unit 210 is omitted. In FIGS. 4 and 5, the drug receiving unit 220 and the drug delivery system 230 may be configured in various forms.
다시 도 2의 설명으로 돌아가면, 약제 수용부(220)는 약제를 수용한다. 본 발명의 일 실시예에 따르면, 약제 수용부(220)는 눈에 전달하기 위한 약제로, 인공눈물, 항생제, 면역억제제, 안압하강제, 진통소염제, 스테로이드제, 항히스타민제, 건성안치료제 등을 수용할 수 있다. 또한, 약제 수용부(220)는 비도의 점막(43)을 통해 인체에 흡수될 수 있도록 하기 위한 약제로, 혈압하강제, 혈관확장제, 당뇨병치료제 등을 수용할 수 있다.2 again, the drug receiving unit 220 receives a drug. According to an embodiment of the present invention, the drug receiving unit 220 is a drug for delivering to the eye, artificial tears, antibiotics, immunosuppressive agents, intraocular pressure lowering agents, analgesic anti-inflammatory drugs, steroids, antihistamines, dry eye treatments, etc. can do. In addition, the drug receiving unit 220 is a drug to be absorbed by the human body through the nasal mucosa 43, it may contain a blood pressure lowering agent, vasodilator, diabetes treatment.
본 발명의 일 실시예에 따르면, 약제 수용부(220)는 비루관 튜브(200)의 일단 또는 양단에 위치할 수 있다. 약제 수용부(220)가 비루관 튜브(200)의 양단에 위치하는 경우, 일단만 위치하는 것보다 많은 양의 약제를 수용할 수 있다.According to one embodiment of the invention, the drug receiving unit 220 may be located at one end or both ends of the nasolacrimal tube 200. When the drug receiving unit 220 is located at both ends of the nasolacrimal duct 200, it is possible to receive a larger amount of drug than to be located only once.
다만, 약제 수용부(220)의 위치는 이에 한정되는 것은 아니고, 약제수용부(220)가 비루관 튜브(200)의 중앙부에 위치할 수도 있다. 특히, 약제 수용부(220)는 약제 배출부(210)가 복수 개 형성되는 경우, 복수 개의 약제 배출부(210) 사이에 위치할 수 있다. 도 6을 참조하여 설명한다.However, the position of the drug receiving unit 220 is not limited thereto, and the drug receiving unit 220 may be located at the center of the nasolacrimal tube 200. In particular, the drug receiving unit 220 may be located between the plurality of drug discharge unit 210, when a plurality of drug discharge unit 210 is formed. It demonstrates with reference to FIG.
도 6은 본 발명의 일 실시예에 따른 비루관 튜브에서 약제 수용부의 위치를 나타내는 도면이다.Figure 6 is a view showing the position of the drug receiving portion in the nasolacrimal duct tube according to an embodiment of the present invention.
도 6을 참조하면, 약제 수용부(220)는 복수 개의 약제 배출부(210) 사이에 위치한다. 도 6에서는 약제 전달 시스템(230)이 약제 배출부(210) 뒤쪽에 위치하여 약제 수용부(220)에 수용된 약제를 밀어내어 약제 배출부(210)로 전달하는 구조를 도시하고 있어, 복수 개의 약제 배출부(210) 사이에 위치한 약제 수용부(220)가 2개로 도시되었다. 하지만, 약제 전달 시스템(230)이 약제 배출부(210) 앞쪽에 위치하여 약제 수용부(220)에 수용된 약제를 끌어당겨 약제 배출부(210)로 전달하는 구조에서는 복수 개의 약제 배출부(210) 사이에 위치한 약제 수용부(220)가 1개 일 수 있으며, 이때, 약제 전달 시스템(230)이 2개가 될 수 있다. 약제 수용부(220)와 약제 전달 시스템(230)의 위치 구조는 아래에서 상세히 설명하도록 한다.Referring to FIG. 6, the drug receiving unit 220 is positioned between the plurality of drug discharge units 210. 6 illustrates a structure in which the drug delivery system 230 is located at the rear of the drug discharge unit 210 and pushes the drug contained in the drug receiving unit 220 to deliver the drug to the drug discharge unit 210. The drug receiving portion 220 located between the discharge portion 210 is shown in two. However, in the structure in which the drug delivery system 230 is located in front of the drug discharge unit 210 to draw the drug contained in the drug receiving unit 220 to deliver to the drug discharge unit 210 a plurality of drug discharge unit 210 There may be one drug receiving unit 220 located therebetween, and at this time, the drug delivery system 230 may be two. The location structure of the drug receiving unit 220 and the drug delivery system 230 will be described in detail below.
다시 도 2의 설명으로 돌아가면, 본 발명의 일 실시예에 따르면, 약제 수용부(220)의 용량은 비루관 튜브(200)의 굵기에 따라 달라질 수 있다. 즉, 비루관 튜브(200)가 굵을수록 약제 수용부(220)의 용량이 커지고, 비루관 튜브(200)가 얇을수록 약제 수용부(220)의 용량이 작아질 수 있다. 따라서, 투약량에 따라 비루관 튜브(200)의 굵기가 결정될 수 있다. 예를 들어, 안구 건조증 환자의 경우, 짧은 주기로 인공 눈물의 투약이 필요하여 큰 용량의 약제 수용부(220)가 필요하므로, 굵은 비루관 튜브(200)를 선택할 수 있다. 이와 반대로 투약량이 작은 경우에는 얇은 비루관 튜브(200)를 선택할 수 있다.2 again, according to one embodiment of the present invention, the dose of the drug receiving unit 220 may vary depending on the thickness of the nasolacrimal tube 200. That is, the larger the nasal tube tube 200, the larger the dose of the drug receiving unit 220, the thinner the nasal tube tube 200, the smaller the dose of the drug receiving unit 220 may be. Therefore, the thickness of the nasolacrimal tube 200 may be determined according to the dosage. For example, in the case of dry eye patients, since the administration of artificial tears is required in a short cycle and a large dose of the drug receiving unit 220 is required, the thick nasolacrimal tube 200 may be selected. On the contrary, when the dosage is small, the thin nasolacrimal tube 200 may be selected.
본 발명의 일 실시예에 따르면, 약제 수용부(200)는 비루관 튜브(200)에 탈착 가능하게 형성될 수 있다. 약제 수용부(200)를 탈착 가능하도록 구성함으로써 비루관 튜브(200)를 환자에 삽입한 채로 보다 편리하게 약제를 보충하거나, 다른 약제로 교체할 수 있다. 약제 수용부(200)는 단독으로 탈착하는 것도 가능하고, 약제 전달 시스템(230)과 같이 탈착할 수도 있다.According to one embodiment of the invention, the drug receiving portion 200 may be formed detachably to the nasolacrimal tube 200. By configuring the drug receiving unit 200 to be detachable, it is possible to more conveniently replenish the medicine while replacing the nasolacrimal tube 200 to the patient, or replace with another medicine. The drug receiving unit 200 may be detachable alone, or may be detached like the drug delivery system 230.
약제 전달 시스템(230)은 약제 수용부(220)에 수용된 약제를 비루관 튜브(200)를 통해 약제 배출부(210)로 전달한다. 본 발명의 일 실시예에 따르면, 약제 전달 시스템(230)은 약제를 이동시키기 위한 피스톤(240)을 포함할 수 있다. 피스톤(240)은 약제를 밀거나 끌어서 약제를 이동시킬 수 있다.The drug delivery system 230 delivers the drug contained in the drug receiving unit 220 to the drug discharge unit 210 through the nasolacrimal tube 200. According to one embodiment of the invention, the drug delivery system 230 may include a piston 240 for moving the drug. The piston 240 may move the drug by pushing or dragging the drug.
본 발명의 일 실시예에 따르면, 약제 전달 시스템(230)은 약제 수용부(220)의 후방에 형성되고, 약제 수용부(230)에 수용된 약제를 밀어내어 약제 배출부(210)로 전달할 수 있다. 도 2를 참조하면, 약제 전달 시스템(230)은 약제 배출부(210)를 기준으로 약제 수용부(220)의 뒤쪽에 형성되어 있다. 이러한 구조에서 약제 전달 시스템(230)은 약제 수용부(220)에 수용된 약제를 밀어내어 약제 배출부(210)로 전달한다.According to one embodiment of the present invention, the drug delivery system 230 is formed at the rear of the drug receiving unit 220, it can push the drug contained in the drug receiving unit 230 to deliver to the drug discharge unit 210. . Referring to FIG. 2, the drug delivery system 230 is formed at the rear of the drug receiver 220 based on the drug discharge unit 210. In this structure, the drug delivery system 230 pushes the drug contained in the drug receiving unit 220 and delivers the drug to the drug discharge unit 210.
이때, 본 발명의 일 실시예에 따르면, 약제 전달 시스템(230)은 탄성 부재(710) 및 팽창 물질을 수용하는 팽창 물질 수용부(810) 중 적어도 하나 이상을 포함할 수 있다. 또한, 약제 전달 시스템(230)은 적어도 둘 이상의 반응 물질을 각각 수용하는 적어도 하나 이상의 반응 물질 수용부(910, 920) 및 상기 적어도 둘 이상의 반응 물질이 만나 반응하는 반응부(930)를 포함할 수 있다. 도 7 내지 도 9를 참조하여 설명한다.At this time, according to an embodiment of the present invention, the drug delivery system 230 may include at least one or more of the elastic member 710 and the expansion material receiving portion 810 for receiving the expansion material. In addition, the drug delivery system 230 may include at least one or more reactant accommodating portions 910 and 920 respectively accommodating at least two or more reactants and a reacting portion 930 where the at least two or more reactants meet and react. have. This will be described with reference to FIGS. 7 to 9.
도 7은 본 발명의 일 실시예에 따른 탄성 부재를 포함하는 약제 전달 시스템을 나타내는 도면이다.7 is a view showing a drug delivery system including an elastic member according to an embodiment of the present invention.
도 7을 참조하면, 탄성 부재(710)의 일 측은 약제 수용부(220)와 약제 전달 시스템(230)을 구분하는 피스톤(240)과 연결되고 다른 일 측은 고정되어 있다. 탄성 부재(710)는 피스톤(240)을 밀어 약제 수용부(220)에 수용된 약제를 밀어낸다. 본 발명의 일 실시예에 따른 탄성 부재(710)는 스프링, 복원력을 갖는 형상 기억 합금 등 다양한 부재가 사용될 수 있다. 도 7에서는 코일 스프링이 탄성 부재(710)로 도시되어 있다. 이러한 탄성 부재(710)는 에너지를 응축하고 있다가 특정 조건하에서 트리거 되면 복원력에 의해 피스톤(240)을 밀어낸다. 여기서 특정 조건은 온도, 사용자의 조작 등이 될 수 있다.Referring to FIG. 7, one side of the elastic member 710 is connected to the piston 240 that separates the drug receiving unit 220 and the drug delivery system 230, and the other side is fixed. The elastic member 710 pushes the piston 240 to push out the medicine contained in the medicine container 220. In the elastic member 710 according to the exemplary embodiment, various members, such as a spring and a shape memory alloy having a restoring force, may be used. In FIG. 7, the coil spring is shown as an elastic member 710. The elastic member 710 condenses energy and, when triggered under a specific condition, pushes the piston 240 by the restoring force. The specific condition may be a temperature, a user's operation, or the like.
도 8은 본 발명의 일 실시예에 따른 팽창 물질 수용부를 포함하는 약제 전달 시스템을 나타내는 도면이다.8 is a view showing a drug delivery system including an expandable substance receiving portion according to an embodiment of the present invention.
도 8을 참조하면, 팽창 물질 수용부(810)의 일 측은 약제 수용부(220)와 약제 전달 시스템(230)을 구분하는 피스톤(240)과 연결되고 다른 일 측은 고정되어 있다. 팽창 물질 수용부(810)에 수용된 팽창 물질이 팽창하며 피스톤(240)을 밀어 약제 수용부(220)에 수용된 약제를 밀어낸다. 본 발명의 일 실시예에 따른 팽창 물질은 특정 온도, 바람직하게는 상온 또는 체온과 비슷한 온도에서 팽창하는 기체 또는 액체가 될 수 있다. 이러한 팽창 물질은 특정 조건 하에서 트리거 되면 팽창을 시작하여 피스톤(240)을 밀어낸다. 여기서 특정 조건은 온도, 기압 등이 될 수 있다. 도 8에서는 팽창 물질 수용부(810)와 약제 전달 시스템(230)이 동일하게 도시되어 있다. 하지만 이에 한정되지 않고 약제 전달 시스템(230) 내에 팽창 물질 수용부(810)가 위치하는 등의 방법으로, 약제 전달 시스템(230)과 팽창물질 수용부(810)가 분리되어 구성될 수도 있다.Referring to FIG. 8, one side of the expanded material receiver 810 is connected to a piston 240 that separates the drug receiver 220 and the drug delivery system 230, and the other side is fixed. The expansion material contained in the expansion material receiver 810 expands and pushes the piston 240 to push out the medicine contained in the medicine receiver 220. The expandable material according to one embodiment of the present invention may be a gas or a liquid which expands at a certain temperature, preferably at or near room temperature. This expansion material, when triggered under certain conditions, initiates expansion and pushes the piston 240. The specific condition may be temperature, air pressure, and the like. In FIG. 8, the inflation substance receiver 810 and the drug delivery system 230 are shown identically. However, the present invention is not limited thereto, and the drug delivery system 230 and the expandable material receiver 810 may be separated from each other by a method such that the expanded material receiver 810 is located in the drug delivery system 230.
도 9은 본 발명의 일 실시예에 따른 반응 물질 수용부 및 반응부를 포함하는 약제 전달 시스템을 나타내는 도면이다. 도 9를 참조하면, 반응부(930)의 일 측은 약제 수용부(220)와 약제 전달 시스템(230)을 구분하는 피스톤(240)과 연결되고 다른 일 측은 고정되어 있다. 또한, 제1 반응 물질 수용부(910)와 제2 반응 물질 수용부(920)는 차단막(940)으로 분리되어 있다. 특정 조건하에서 차단막(940)이 제거되면, 제1 반응 물질 수용부(910)와 제2 반응 물질 수용부(920)에 수용된 제1 반응 물질과 제2 반응 물질이 반응부(930) 내에서 반응하여 팽창하며 피스톤(240)을 밀어 약제 수용부(220)에 수용된 약제를 밀어낸다. 본 발명의 일 실시예에 따른 반응 물질들은 서로 만나 반응하며 팽창하는 물질이 될 수 있다. 본 발명의 일 실시예에 따른 차단막(940)은 외부 힘 또는 특정 온도에서 제거될 수 있다. 또한, 도 9에서는 제1 반응 물질 수용부(910)와 제2 반응 물질 수용부(920)가 차단막(940)으로 구분되어 있으나, 다른 다양한 방법으로 분리될 수도 있다. 나아가, 도 9에서는 반응부(930)와 약제 전달 시스템(230)이 동일하게 도시되어 있고, 반응부(930) 내에 제1 반응 물질 수용부(910)와 제2 반응 물질 수용부(920)가 포함되어 있다. 하지만 이에 한정되지 않고 약제 전달 시스템(230) 내에 반응부(930)가 위치하고, 반응부(930)가 제1 반응 물질 수용부(910)와 제2 반응 물질 수용부(920)와 별도의 공간으로 존재하는 등의 방법으로, 약제 전달 시스템(230)과 반응부(930), 제1 반응 물질 수용부(910) 및 제2 반응 물질 수용부(920)가 분리되어 구성될 수도 있다.9 is a view showing a drug delivery system including a reactant receiving portion and a reaction portion according to an embodiment of the present invention. 9, one side of the reaction unit 930 is connected to the piston 240 that separates the drug receiving unit 220 and the drug delivery system 230, and the other side is fixed. In addition, the first reactant accommodating part 910 and the second reactant accommodating part 920 are separated by a blocking film 940. When the blocking layer 940 is removed under specific conditions, the first reactant and the second reactant contained in the first reactant accommodating part 910 and the second reactant accommodating part 920 react in the reaction part 930. By expanding and pushing the piston 240 pushes the drug contained in the drug receiving portion 220. Reactive materials according to an embodiment of the present invention may be a material that meets and reacts with each other and expands. The blocking film 940 according to an embodiment of the present invention may be removed at an external force or a specific temperature. In addition, although the first reactant accommodating part 910 and the second reactant accommodating part 920 are divided into the blocking film 940 in FIG. 9, they may be separated by other various methods. Furthermore, in FIG. 9, the reaction unit 930 and the drug delivery system 230 are shown in the same manner, and the first reactant accommodating part 910 and the second reactant accommodating part 920 are formed in the reaction part 930. Included. However, the present invention is not limited thereto, and the reaction unit 930 is located in the drug delivery system 230, and the reaction unit 930 is a separate space from the first reactant accommodating part 910 and the second reactant accommodating part 920. As such, the drug delivery system 230 and the reaction unit 930, the first reactant accommodating part 910, and the second reactant accommodating part 920 may be separated from each other.
본 발명의 일 실시예에 따르면, 약제 전달 시스템(230)은 약제 수용부(220)의 전방에 형성되고, 약제 수용부(220)에 수용된 약제를 끌어당겨 약제 배출부(210)로 전달할 수 있다. 도 10을 참조하여 설명한다.According to one embodiment of the present invention, the drug delivery system 230 is formed in front of the drug receiving unit 220, may be delivered to the drug discharge unit 210 by pulling the drug contained in the drug receiving unit 220. . It demonstrates with reference to FIG.
도 10은 본 발명의 일 실시예에 따른 비루관 튜브에서 약제 전달 시스템의 위치를 나타내는 도면이다.10 is a view showing the position of the drug delivery system in the nasolacrimal tube according to an embodiment of the present invention.
도 10을 참조하면, 약제 전달 시스템(230)은 약제 배출부(210)를 기준으로 약제 수용부(220)의 앞쪽에 형성되어 있다. 이러한 구조에서 약제 전달 시스템(230)은 약제 수용부(220)에 수용된 약제를 끌어당겨 약제 배출부(210)로 전달한다. 본 발명의 일 실시예에 따르면, 약제 전달 시스템(230)은 펌프(미도시)를 포함할 수 있다. 이때, 펌프는 에어리스 펌프일 수 있다. 펌프는 약제 수용부에 수용된 약제를 펌핑하여 약제 배출부로 전달할 수 있다.Referring to FIG. 10, the drug delivery system 230 is formed at the front of the drug receiving unit 220 based on the drug discharge unit 210. In this structure, the drug delivery system 230 pulls the drug contained in the drug receiving unit 220 and delivers the drug to the drug discharge unit 210. According to one embodiment of the invention, the drug delivery system 230 may comprise a pump (not shown). In this case, the pump may be an airless pump. The pump may pump the medicine contained in the medicine container and deliver the medicine to the medicine discharge part.
또한, 본 발명의 일 실시예에 따른 약제 전달 시스템(230)은 비루관 튜브(200)에 탈착 가능하게 형성될 수 있다. 약제 전달 시스템(230)를 탈착 가능하도록 구성함으로써 약제 전달 시스템(230)의 에너지(탄성 에너지, 반응 에너지 등)가 소진된 경우, 보다 편리하게 약제 전달 시스템(230)을 교체할 수 있다. 약제 전달 시스템(230)은 단독으로 탈착하는 것도 가능하고, 약제 수용부(200)와 같이 탈착할 수도 있다.In addition, the drug delivery system 230 according to an embodiment of the present invention may be detachably formed in the nasolacrimal tube 200. By configuring the drug delivery system 230 to be detachable, when the energy (elastic energy, reaction energy, etc.) of the drug delivery system 230 is exhausted, the drug delivery system 230 may be replaced more conveniently. The drug delivery system 230 may be detachably detached, or may be detachably attached to the drug receiving unit 200.
나아가, 본 발명의 일 실시예에 따른 비루관 튜브(200)는 비루관 튜브(200)가 삽입된 경우에도, 눈물이 원활하게 배출될 수 있도록 누점을 막지 않을 정도의 굵기로 형성될 수 있다. 보다 구체적으로, 비루관 튜브(200)는 그 둘레가 사람의 평균 누점 둘레보다 작은 정도의 굵기로 형성될 수 있다. 이때, 눈물 배출을 보다 원활하게 하기 위하여 비루관 튜브(200)는 누점에 대응되는 위치에서 다른 위치보다 가늘게 형성될 수 있다.In addition, the nasolacrimal duct tube 200 according to an embodiment of the present invention may be formed to a thickness that does not block the punctate so that tears can be smoothly discharged even when the nasolacrimal duct 200 is inserted. More specifically, the nasolacrimal duct 200 may be formed to a thickness such that the circumference thereof is smaller than the average puncturing circumference of the person. At this time, in order to smooth the discharge of tears nasal tube tube 200 may be formed thinner than other positions in the position corresponding to the punctate.
본 발명의 일 실시예에 따른 가요성 튜브의 재질은 실리콘일 수 있다. 또한, 누도에 삽입이 용이하도록 실리콘 튜브보다는 경도가 있는 재질을 이용하는 것이 바람직하다. 예를 들어, 폴리올레핀, 폴리아미드 또는 폴리우레탄 단독 또는 그들의 혼합물의 군으로부터 선택한 재료로 구성할 수도 있다.The material of the flexible tube according to the embodiment of the present invention may be silicon. In addition, it is preferable to use a material having a hardness rather than a silicon tube to facilitate insertion into the fistula. For example, it may be composed of a material selected from the group of polyolefins, polyamides or polyurethanes alone or mixtures thereof.
본 발명에 따르면, 환자에게 안정적이고 지속적으로 약물을 전달할 수 있다. 또한, 약제가 간을 통과하지 않으면서도 약제의 전신적이고 지속적인 투약이 가능하다.According to the present invention, the drug can be delivered to the patient stably and continuously. In addition, systemic and sustained administration of the drug is possible without the drug passing through the liver.
본 발명의 일 실시예에 따른 비루관 삽입용 기구는, 비루관을 따라 삽입되고 가요성을 갖는 비루관 튜브(200), 약제를 수용하는 약제 수용부(220), 약제가 상기 비루관 튜브의 외부로 배출될 수 있도록 형성되는 약제 배출부(210) 및 약제 수용부(220)에 수용된 약제를 비루관 튜브(200)를 통해 약제 배출부(210)로 전달하는 약제 전달 시스템(230)을 포함한다. 각 구성은 위에서 설명한 비루관 튜브의 구성과 동일한 바, 중복되는 설명은 생략하도록 한다.Nasal tube insertion mechanism according to an embodiment of the present invention, the nasal tube tube 200 is inserted along the nasolacrimal tube and flexible, the drug receiving unit 220 for receiving a drug, the drug is discharged to the outside of the nasal tube tube It includes a drug delivery system 230 to deliver the drug contained in the drug discharge unit 210 and the drug receiving unit 220 to the drug discharge unit 210 through the nasal duct tube 200. Each configuration is the same as the configuration of the nasolacrimal tube described above, so that duplicate description will be omitted.
본 발명의 일 실시예에 따른 비루관 삽입용 기구는 비루관을 따라 삽입되고 가요성을 갖는 튜브의 양단에 한 쌍의 프로브나 가이드를 더 포함할 수도 있다. 이러한, 비루관을 따라 삽입되고 가요성을 갖는 튜브 또는 프로브나 가이드의 형태는 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 자명한 범위 내에서 다양한 형태를 가질 수 있다.The nasolacrimal catheter insertion apparatus according to an embodiment of the present invention may further include a pair of probes or guides inserted at both ends of the nasolacrimal tube and flexible. Such a form of a tube or probe or guide inserted along the nasolacrimal duct and having flexibility may have various forms within the scope obvious to those skilled in the art.
또한, 본 발명의 일 실시예에 따른 비루관 삽입용 기구는, 하기와 같은 방법으로 삽입될 수 있다.In addition, the nasolacrimal duct insertion instrument according to an embodiment of the present invention may be inserted in the following manner.
먼저, 상하의 누점(41a, 41b)을 통해 프로브를 각각 삽입하고, 외부로 인출시킨 뒤, 프로브의 안내 작용에 의해, 누점(41a, 41b)으로부터 비도(42)로 비루관 튜브(200)가 삽입되도록 할 수 있다. 그 다음, 누점(41a, 41b) 또는 비도(42)에 약제 배출부(210)가 위치하도록 비루관 튜브(200)의 위치를 조절할 수 있다. 나아가, 비루관 튜브(200)는 길이 조절부를 포함할 수 있으며, 이러한 길이 조절부를 이용하여 원하는 위치에 약제 배출부(210)가 위치하도록 비루관 튜브(200)의 길이 및 위치를 조절할 수 있다.First, the probes are respectively inserted through the upper and lower punctures 41a and 41b, and withdrawn to the outside, and the nasolacrimal tube 200 is inserted into the nasal passages 42 from the puncturing holes 41a and 41b by the guiding action of the probes. can do. Next, the position of the nasal duct tube 200 may be adjusted such that the drug discharge part 210 is positioned in the punctal tract 41a or 41b or the nasal passage 42. In addition, the nasolacrimal tube 200 may include a length adjusting unit, and the length and position of the nasolacrimal tube 200 may be adjusted such that the drug discharge unit 210 is positioned at a desired position using the length adjusting unit.
그 후, 필요에 따라 프로브를 튜브(200)로부터 분리시키고, 비루관 튜브(200)의 선단끼리를 결절이 형성되도록 매듭지음으로써, 비루관 튜브(200)를 고정시켜, 비루관 튜브(200)가 체내에 남아 누도의 연통 상태를 유지하도록 할 수 있다. 이러한 비루관 삽입용 기구의 장착 방법 역시 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 자명한 범위 내에서 다양하게 이루어질 수 있다.Thereafter, if necessary, the probe is detached from the tube 200 and the nasal tube tube 200 is knotted to form a nodule, thereby fixing the nasolacrimal tube 200 so that the nasolacrimal tube 200 is inserted into the body. It is possible to maintain the communication status of the male fistula. The mounting method of the nasolacrimal insertion device may also be variously made within a range obvious to those skilled in the art.
본 명세서와 도면에 개시된 본 발명의 실시예들은 본 발명의 기술내용을 쉽게 설명하고 본 발명의 이해를 돕기 위해 특정 예를 제시한 것일 뿐이며,본 발명의 범위를 한정하고자 하는 것은 아니다. 여기에 개시된 실시예들 이외에도 본 발명의 기술적 사상에 바탕을 둔 다른 변형 예들이 실시 가능하다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 자명한 것이다.Embodiments of the present invention disclosed in the specification and drawings are only specific examples to easily explain the technical details of the present invention and to help understanding of the present invention, and are not intended to limit the scope of the present invention. It will be apparent to those skilled in the art that other modifications based on the technical idea of the present invention can be carried out in addition to the embodiments disclosed herein.

Claims (16)

  1. 비루관을 따라 삽입되고 가요성을 갖는 비루관 튜브에 있어서,In a nasal canal tube inserted along a nasal canal and having flexibility,
    약제를 수용하는 약제 수용부;Drug receiving unit for receiving a drug;
    상기 약제가 상기 비루관 튜브의 외부로 배출되는 약제 배출부; 및A drug discharge part for discharging the drug to the outside of the nasolacrimal duct tube; And
    상기 약제 수용부에 수용된 상기 약제를 상기 비루관 튜브를 통해 상기 약제배출부로 전달하는 약제 전달 시스템을 포함하는 것을 특징으로 하는 비루관 튜브.Nasal tube tube characterized in that it comprises a drug delivery system for delivering the drug contained in the drug receiving portion to the drug discharge through the nasal tube.
  2. 제1항에 있어서,The method of claim 1,
    상기 약제 전달 시스템은,The drug delivery system,
    상기 약제 수용부의 후방에 형성되고, 상기 약제 수용부에 수용된 상기 약제를 밀어내어 상기 약제 배출부로 전달하는 것을 특징으로 하는 비루관 튜브.It is formed in the rear of the drug receiving portion, nasal tube tube, characterized in that for pushing the drug contained in the drug receiving portion and delivered to the drug discharge.
  3. 제2항에 있어서,The method of claim 2,
    상기 약제 전달 시스템은,The drug delivery system,
    탄성 부재 및 팽창 물질을 수용하는 팽창 물질 수용부 중 적어도 하나 이상을 포함하는 것을 특징으로 하는 비루관 튜브.A nasal canal tube comprising at least one of an elastic member and an expandable material receptacle for receiving the expanded material.
  4. 제2항에 있어서,The method of claim 2,
    상기 약제 전달 시스템은,The drug delivery system,
    적어도 둘 이상의 반응 물질을 각각 수용하는 복수 개의 반응 물질 수용부; 및 A plurality of reactant accommodating portions, each receiving at least two or more reactants; And
    상기 적어도 둘 이상의 반응 물질이 만나 반응하는 반응부를 포함하는 것을The at least two reactants include a reaction unit that meets and reacts
    특징으로 하는 비루관 튜브.Characterized in that the nasolacrimal tube.
  5. 제1항에 있어서,The method of claim 1,
    상기 약제 전달 시스템은,The drug delivery system,
    상기 약제 수용부의 전방에 형성되고, 상기 약제 수용부에 수용된 상기 약제를 끌어당겨 상기 약제 배출부로 전달하는 것을 특징으로 하는 비루관 튜브.Is formed in front of the drug receiving portion, the nasal tube tube, characterized in that to pull the drug contained in the drug receiving portion and to deliver to the drug discharge.
  6. 제5항에 있어서,The method of claim 5,
    상기 약제 전달 시스템은, The drug delivery system,
    펌프를 포함하는 것을 특징으로 하는 비루관 튜브.Nasal tube tube, characterized in that it comprises a pump.
  7. 제1항에 있어서,The method of claim 1,
    상기 약제 전달 시스템은,The drug delivery system,
    상기 약제를 이동시키기 위한 피스톤을 포함하는 것을 특징으로 하는 비루관 튜브.Nasal tube, characterized in that it comprises a piston for moving the drug.
  8. 제1항에 있어서,The method of claim 1,
    상기 약제 배출부는,The drug discharge unit,
    상기 비루관 튜브 삽입 시, 누점 및 비도 중 적어도 하나 이상의 지점에 대응되는 위치에 형성되는 것을 특징으로 하는 비루관 튜브.When the nasolacrimal tube is inserted, a nasolacrimal tube is formed at a position corresponding to at least one or more points of punctate and nasal passage.
  9. 제1항에 있어서,The method of claim 1,
    상기 약제 수용부는,The drug receiving unit,
    상기 비루관 튜브의 일단 또는 양단에 위치하는 것을 특징으로 하는 비루관 튜브.Nasal tube tube, characterized in that located in one or both ends of the nasal tube.
  10. 제1항에 있어서,The method of claim 1,
    상기 약제 수용부는,The drug receiving unit,
    상기 약제 배출부가 복수 개 형성되는 경우, 복수 개의 상기 약제 배출부 사이에 위치하는 것을 특징으로 하는 비루관 튜브.When a plurality of drug discharge portion is formed, nasal tube tube, characterized in that located between the plurality of drug discharge portion.
  11. 제1항에 있어서,The method of claim 1,
    상기 약제 수용부 및 상기 약제 배출 시스템 중 적어도 하나 이상은,At least one or more of the drug receiving portion and the drug discharge system,
    상기 비루관 튜브에 탈착 가능하게 형성되는 것을 특징으로 하는 비루관 튜브.A nasal tube tube, characterized in that the detachable to the nasal tube tube.
  12. 제1항에 있어서,The method of claim 1,
    상기 비루관 튜브는,The nasolacrimal tube is
    누점을 막지 않을 정도의 굵기로 형성되는 것을 특징으로 하는 비루관 튜브.A nasolacrimal duct tube characterized in that it is formed to a thickness so as not to block a punctate.
  13. 제12항에 있어서,The method of claim 12,
    상기 비루관 튜브는,The nasolacrimal tube is
    상기 누점에 대응되는 위치에서 다른 위치보다 가늘게 형성되는 것을 특징으로 하는 비루관 튜브.Nasal tube tube, characterized in that formed in the thinner than the other position at the position corresponding to the punctate.
  14. 제1항에 있어서,The method of claim 1,
    상기 약제 배출부는, The drug discharge unit,
    적어도 하나 이상의 개구부를 포함하는 것을 특징으로 하는 비루관 튜브.A nasolacrimal tube comprising at least one opening.
  15. 제1항에 있어서,The method of claim 1,
    상기 약제 배출부는, The drug discharge unit,
    개폐 가능하도록 형성되는 것을 특징으로 하는 비루관 튜브.Nasal tube tube, characterized in that formed to be open and close.
  16. 비루관 삽입용 기구에 있어서, In the nasal tube insertion instrument,
    비루관을 따라 삽입되고 가요성을 갖는 비루관 튜브;Nasal tube tubes inserted along the nasal tube and having flexibility;
    약제를 수용하는 약제 수용부;Drug receiving unit for receiving a drug;
    상기 약제가 상기 비루관 튜브의 외부로 배출되는 약제 배출부; 및A drug discharge part for discharging the drug to the outside of the nasolacrimal duct tube; And
    상기 약제 수용부에 수용된 상기 약제를 상기 비루관 튜브를 통해 상기 약제 배출부로 전달하는 약제 전달 시스템을 포함하는 것을 특징으로 하는 비루관 삽입용 기구.And a drug delivery system for delivering the drug contained in the medicine container to the drug discharge part through the nasal pipe tube.
PCT/KR2017/004663 2016-05-02 2017-05-02 Nasolacrimal duct tube and mechanism for inserting nasolacrimal duct WO2017191987A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0053810 2016-05-02
KR1020160053810A KR101846532B1 (en) 2016-05-02 2016-05-02 Nasolacrimal duct tube and insertion appliance for nasolacrimal duct

Publications (1)

Publication Number Publication Date
WO2017191987A1 true WO2017191987A1 (en) 2017-11-09

Family

ID=60203046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/004663 WO2017191987A1 (en) 2016-05-02 2017-05-02 Nasolacrimal duct tube and mechanism for inserting nasolacrimal duct

Country Status (2)

Country Link
KR (1) KR101846532B1 (en)
WO (1) WO2017191987A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102204175B1 (en) 2018-11-29 2021-01-18 (주)파로스테크메디칼 Nasolacrimal duct insertion tool with endoscope insertion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09276318A (en) * 1996-04-08 1997-10-28 M L C:Kk Insertion tool for pipe in lacrimal duct
US20110311606A1 (en) * 2010-06-18 2011-12-22 Coldren Bret A Punctal plugs with continuous or pulsatile drug release mechanism
KR20130040867A (en) * 2010-04-08 2013-04-24 존슨 앤드 존슨 비젼 케어, 인코포레이티드 Punctal plugs for controlled release of therapeutic agents
US20130184661A1 (en) * 2012-01-16 2013-07-18 Stephen R. Beaton Eye drug delivery system
KR101425636B1 (en) * 2013-07-05 2014-08-01 임한웅 Nasolacrimal duct tube with lacrimal passage

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09276318A (en) * 1996-04-08 1997-10-28 M L C:Kk Insertion tool for pipe in lacrimal duct
KR20130040867A (en) * 2010-04-08 2013-04-24 존슨 앤드 존슨 비젼 케어, 인코포레이티드 Punctal plugs for controlled release of therapeutic agents
US20110311606A1 (en) * 2010-06-18 2011-12-22 Coldren Bret A Punctal plugs with continuous or pulsatile drug release mechanism
US20130184661A1 (en) * 2012-01-16 2013-07-18 Stephen R. Beaton Eye drug delivery system
KR101425636B1 (en) * 2013-07-05 2014-08-01 임한웅 Nasolacrimal duct tube with lacrimal passage

Also Published As

Publication number Publication date
KR101846532B1 (en) 2018-04-09
KR20170124211A (en) 2017-11-10

Similar Documents

Publication Publication Date Title
US8870826B2 (en) Combined otic aspirator and medication dispenser
CN103826581B (en) For anaesthetizing personalization system and the method for eardrum
EP2160219B1 (en) Gastric space filler device and delivery system
US5611787A (en) Method and device for gastric line insertion
WO2020197995A1 (en) Nasal drug delivery system
WO2017191987A1 (en) Nasolacrimal duct tube and mechanism for inserting nasolacrimal duct
WO2010074497A2 (en) Terminal connecting device for injection fluid injection apparatus
WO2015002510A1 (en) Nasolacrimal duct tube including lachrymal passage
WO2020013467A1 (en) Urinary tract catheter
WO2022114645A1 (en) Nasopharyngeal airway management device for brain-nasal cavity cooling
WO2021045311A1 (en) Urethral stricture inhibiting apparatus
WO2022092503A2 (en) Urethral catheterization apparatus
CN111938559A (en) Novel enteroscope for digestive system department
JP2010154917A (en) Endoscope insertion assisting device
WO2020116778A1 (en) Liquid medicine injector comprising bolus counter
WO2018217000A1 (en) Device for changing mouth/nose position of nasobiliary drainage tube
WO2015122681A1 (en) Lens capsule incision device
KR20120088510A (en) Catheter guide for treating ectopic pregnancy and catheter unit with the same
WO2022149817A1 (en) Nasal cannula and medical equipment including same
WO2013191317A1 (en) Device for injecting liquid into body, comprising separable sealing member
WO2021157806A1 (en) Catheter having temperature sensor
WO2018093147A1 (en) Infusion set having function of preventing blood leakage and backflow
WO2023014173A1 (en) Vaginally insertable medicine supply device
WO2020246821A2 (en) Extensible drug injection device and operation method therefor
WO2024128510A1 (en) Device for nasal administration of drug

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17792889

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17792889

Country of ref document: EP

Kind code of ref document: A1